Evidence map›Paper›PMID 40519392›Full record

ArticleCureus2025

Successful Re-administration and Extended Dosing of Brentuximab Vedotin Monotherapy for Relapsed Anaplastic Large Cell Lymphoma in a Vulnerable Patient.

Tomoki Minemura, Shohei Kikuchi, Takuma Fujihira, Yoshimi Nabe, Ryusuke Horaguchi, Yusuke Kamihara, Akinori Wada, Kento Ono, Tsutomu Katou, Tsutomu Sato

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomoki MinemuraDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Shohei KikuchiDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Takuma FujihiraDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Yoshimi NabeDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Ryusuke HoraguchiDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Yusuke KamiharaDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Akinori WadaDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Kento OnoDepartment of Hematology, Toyama University Hospital, Toyama, JPN.
Tsutomu KatouDepartment of Internal Medicine, Toyama Nishi General Hospital, Toyama, JPN.
Tsutomu SatoDepartment of Hematology, Toyama University Hospital, Toyama, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brentuximab vedotin (BV) monotherapy has significant clinical efficacy against relapsed anaplastic large cell lymphoma. While BV monotherapy re-administration and extended duration of treatment show therapeutic potential, particularly in patients ineligible for autologous hematopoietic stem cell transplantation or conventional salvage chemotherapy due to advanced age or poor performance status, long-term administration is frequently limited by cumulative neurotoxicity. Herein, we present a case of successful BV monotherapy re-administration and extended treatment over 4.3 years in a vulnerable patient. This therapeutic approach expands treatment options available for elderly patients and those with poor performance status.

Indexed as

brentuximab vedotin-induced neuropathybrentuximab vedotin treatmentcd30+ anaplastic large cell lymphomachemotherapy-induced peripheral neuropathygeriatric assessmentvulnerable patients

Identifiers

PMID40519392
PMCPMC12162370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.